Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Pfizer | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Pfizer

1Q revenues up 20%

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Pfizer

1Q Revenues: $13.0 billion (+20%)

1Q Earnings: $3.0 billion (+27%)

Comments: Innovative Product sales were $7.0 billion, up 23% driven by Eliquis globally, Lyrica and Xeljanz both primarily in the U.S., Enbrel in most international markets and Chantix primarily in the U.S. Global Vaccines sales were $1.6 billion, up 18%. Global Oncology revenues were $1.0 billion, up 90% driven by Ibrance for advanced breast cancer and, to a lesser extent, stronger demand for Sutent and Xalkori in most markets. Established Product sales were $6.0 billion, up 17%. In September 2015, Pfizer acquired Hospira, its legacy operations contributed $1.2 billion in sales in the quarter. Global Established Pharmaceutical segment sales were $4.8 billion, down 7% due to loss of exclusivity and associated generic competition for certain Peri-LOE Products, primarily Zyvox in the U.S. and certain developed Europe markets as well as Lyrica in certain developed Europe markets. 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters